Arexvy was the first RSV vaccine for older adults to be approved anywhere in the world. It had an exceptional launch and generated £1.2 billion in sales in 2023.

Patients should ask their doctor or pharmacist if Arexvy is covered, GSK advised. [Read more: Kinney Drugs to administer RSV vaccine for adults over age 60 years old] ...

In adults ages 50 to 59 who are at an increased risk for RSV lower respiratory tract disease because of underlying medical conditions, Arexvy triggered an immune response that was non-inferior to ...

The FDA approved the first RSV vaccine Wednesday, called Arexvy, which is designed to be given as a single shot to adults 60 and over.

Well in advance of the fall and winter RSV season, GSK's vaccine Arexvy is now available in major U.S. retail pharmacies, the company said.

GSK (GSK) announces that its Arexvy vaccine shows promise in protecting adults aged 60+ against RSV over three seasons in a Phase 3 trial. Read more here.

Arexvy is currently approved in the United States, Europe, Japan and several other countries in adults aged 60 and more for the prevention of lower respiratory tract disease (LRTD) caused by RSV.